Riken Corporation

Ambicion Co., Ltd.

Tomokuni Shigeura

Masaru Taniguchi

Kenji Mori

Hiroshi Watarai

Takuya Tashiro

Masao Shiozaki

Minako Aihara

Keigo Hanada

The present invention relates to a method for producing en NKT cell ligand-pulsed human CD14 positive cell that activates NKT cells and strongly induces proliferation, IFN-&#x3b3; production, and/or cytotoxic activity of NKT cells. More specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and GM-CSF and substantially free of IL-4. In addition, the present invention relates to a method for producing an NKT cell ligand-pulsed human CD14 positive cell line and, specifically, the method is characterized in that the isolated CD14 positive cell is cultured in a medium containing an NKT cell ligand and substantially free of GM-CSF and IL-4. The present invention also relates to a cell preparation containing an NKT cell ligand-pulsed human CD14 positive cell or an NKT cell ligand-pulsed human CD14 positive cell line and pharmaceutical use thereof.

Technology for efficient activation of NKT cells

The invention provides a compound represented by the formula (I) wherein Ris a hydrogen atom or a hydroxyl group; two Rare the same or different and each is a hydrogen atom or a hydroxyl group; Ris a hydrocarbon group having 8-14 carbon atoms, which optionally has substituent(s); and Ris a hydrocarbon group having 18-24 carbon atoms, which optionally has substituent(s), or a salt thereof. The invention also provides a method of treating an autoimmune disease or suppressing immunity by administering the aforementioned compound or a salt thereof to a patient in need thereof.

Hydroxylated KRN7000 analogue and use thereof

Growing community of inventors

Wako, Japan

Tomokuni Shigeura